{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T07:30:29Z","timestamp":1769499029492,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s10637-011-9732-3","type":"journal-article","created":{"date-parts":[[2011,8,31]],"date-time":"2011-08-31T07:50:03Z","timestamp":1314777003000},"page":"1575-1584","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies"],"prefix":"10.1007","volume":"30","author":[{"given":"Athanassios","family":"Argiris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trevor M.","family":"Feinstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianbing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shruti","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard J.","family":"Appleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald G.","family":"Stoller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer R.","family":"Grandis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann Marie","family":"Egloff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,9,1]]},"reference":[{"issue":"16","key":"9732_CR1","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2006.06.7447","volume":"25","author":"JB Vermorken","year":"2007","unstructured":"Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F et al (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.[see comment]. J Clin Oncol 25(16):2171\u20137","journal-title":"J Clin Oncol"},{"issue":"7","key":"9732_CR2","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","volume":"22","author":"LB Saltz","year":"2004","unstructured":"Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.[see comment]. J Clin Oncol 22(7):1201\u20138","journal-title":"J Clin Oncol"},{"issue":"20","key":"9732_CR3","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa071834","volume":"357","author":"DJ Jonker","year":"2007","unstructured":"Jonker DJ, O\u2019Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au H-J et al (2007) Cetuximab for the treatment of colorectal cancer. New Engl J Med 357(20):2040\u20138","journal-title":"New Engl J Med"},{"issue":"4","key":"9732_CR4","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1073\/pnas.96.4.1415","volume":"96","author":"DA Tice","year":"1999","unstructured":"Tice DA, Biscardi JS, Nickles AL, Parsons SJ (1999) Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc Natl Acad Sci USA 96(4):1415\u201320","journal-title":"Proc Natl Acad Sci USA"},{"issue":"15","key":"9732_CR5","doi-asserted-by":"publisher","first-page":"6981","DOI":"10.1073\/pnas.92.15.6981","volume":"92","author":"MC Maa","year":"1995","unstructured":"Maa MC, Leu TH, McCarley DJ, Schatzman RC, Parsons SJ (1995) Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. Proc Natl Acad Sci USA 92(15):6981\u20135","journal-title":"Proc Natl Acad Sci USA"},{"key":"9732_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ccr.2004.09.001","volume":"6","author":"R Ishizawar","year":"2004","unstructured":"Ishizawar R, Parsons SJ (2004) c-Src and cooperating partners in human cancer. Cancer Cell 6:209\u2013214","journal-title":"Cancer Cell"},{"key":"9732_CR7","doi-asserted-by":"publisher","first-page":"896407","DOI":"10.1155\/2009\/896407","volume":"2009","author":"AM Egloff","year":"2009","unstructured":"Egloff AM, Grandis JR (2009) Improving response rates to EGFR-targeted therapies for head and neck squamous cell carcinoma: candidate predictive biomarkers and combination treatment with Src inhibitors. J Oncol 2009:896407","journal-title":"J Oncol"},{"issue":"4","key":"9732_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1023\/A:1023772912750","volume":"22","author":"JM Summy","year":"2003","unstructured":"Summy JM, Gallick GE (2003) Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22(4):337\u201358","journal-title":"Cancer Metastasis Rev"},{"issue":"17","key":"9732_CR9","doi-asserted-by":"publisher","first-page":"6166","DOI":"10.1158\/0008-5472.CAN-04-0504","volume":"64","author":"Q Zhang","year":"2004","unstructured":"Zhang Q, Thomas SM, Xi S, Smithgall TE, Siegfried JM, Kamens J et al (2004) SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res 64(17):6166\u201373","journal-title":"Cancer Res"},{"issue":"13","key":"9732_CR10","doi-asserted-by":"publisher","first-page":"4284","DOI":"10.1158\/1078-0432.CCR-07-5226","volume":"14","author":"P Koppikar","year":"2008","unstructured":"Koppikar P, Choi SH, Egloff AM, Cai Q, Suzuki S, Freilino M et al (2008) Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin Cancer Res 14(13):4284\u201391","journal-title":"Clin Cancer Res"},{"issue":"6","key":"9732_CR11","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1158\/1541-7786.MCR-09-0003","volume":"7","author":"EL-H Leung","year":"2009","unstructured":"Leung EL-H, Tam IY-S, Tin VP-C, Chua DT-T, Sihoe AD-L, Cheng L-C et al (2009) SRC promotes survival and invasion of lung cancers with epidermal growth factor receptor abnormalities and is a potential candidate for molecular-targeted therapy. MolCancer Res: MCR 7(6):923\u201332","journal-title":"MolCancer Res: MCR"},{"issue":"27","key":"9732_CR12","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1021\/jm049486a","volume":"47","author":"LJ Lombardo","year":"2004","unstructured":"Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K et al (2004) Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47(27):6658\u201361","journal-title":"J Med Chem"},{"issue":"11","key":"9732_CR13","doi-asserted-by":"publisher","first-page":"R255","DOI":"10.1186\/gb-2007-8-11-r255","volume":"8","author":"XD Wang","year":"2007","unstructured":"Wang XD, Reeves K, Luo FR, Xu LA, Lee F, Clark E et al (2007) Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring. Genome Biol 8(11):R255","journal-title":"Genome Biol"},{"issue":"4","key":"9732_CR14","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/nchembio.332","volume":"6","author":"J Li","year":"2010","unstructured":"Li J, Rix U, Fang B, Bai Y, Edwards A, Colinge J et al (2010) A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol 6(4):291\u20139","journal-title":"Nat Chem Biol"},{"issue":"25","key":"9732_CR15","doi-asserted-by":"publisher","first-page":"6322","DOI":"10.1182\/blood-2008-11-186817","volume":"113","author":"H Kantarjian","year":"2009","unstructured":"Kantarjian H, Cortes J, Kim DW, Dorlhiac-Llacer P, Pasquini R, DiPersio J et al (2009) Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 113(25):6322\u20139","journal-title":"Blood"},{"issue":"19 Pt 1","key":"9732_CR16","doi-asserted-by":"publisher","first-page":"6924","DOI":"10.1158\/1078-0432.CCR-05-0757","volume":"11","author":"FM Johnson","year":"2005","unstructured":"Johnson FM, Saigal B, Talpaz M, Donato NJ (2005) Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 11(19 Pt 1):6924\u201332","journal-title":"Clin Cancer Res"},{"key":"9732_CR17","doi-asserted-by":"crossref","unstructured":"Wheeler DL, Iida M, Kruser TJ, Nechrebecki MM, Dunn EF, Armstrong EA, et al (2009) Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol Ther 8(8)","DOI":"10.4161\/cbt.8.8.7903"},{"issue":"3","key":"9732_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205\u201316","journal-title":"J Natl Cancer Inst"},{"issue":"30","key":"9732_CR19","doi-asserted-by":"publisher","first-page":"4609","DOI":"10.1200\/JCO.2010.30.5474","volume":"28","author":"FM Johnson","year":"2010","unstructured":"Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT et al (2010) Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 28(30):4609\u201315","journal-title":"J Clin Oncol"},{"issue":"15s","key":"9732_CR20","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.1200\/jco.2009.27.15_suppl.6022","volume":"27","author":"HD Brooks","year":"2009","unstructured":"Brooks HD, Glisson B, Lu C, Sabichi A, Johnson F, Ginsberg L et al (2009) Phase II study of dasatinib in the treatment of head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 27(15s):abstr 6022","journal-title":"J Clin Oncol"},{"issue":"8","key":"9732_CR21","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1200\/JCO.2009.25.4029","volume":"28","author":"EB Haura","year":"2010","unstructured":"Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S et al (2010) Phase I\/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol 28(8):1387\u201394","journal-title":"J Clin Oncol"},{"key":"9732_CR22","doi-asserted-by":"crossref","unstructured":"Luo FR, Barrett Y, Ji P, Holly P, McCann E, Rhyne P et al (2006) Dasatinib (BMS-354825) pharmacokinetics correlate with pSRC pharmacodynamics in phase I studies of patients with cancer: Results from CA180003. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 3046 2006","DOI":"10.1200\/jco.2006.24.18_suppl.3046"},{"issue":"7","key":"9732_CR23","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1158\/1078-0432.CCR-08-1627","volume":"15","author":"AJ Mutsaers","year":"2009","unstructured":"Mutsaers AJ, Francia G, Man S, Lee CR, Ebos JM, Wu Y et al (2009) Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent. Clin Cancer Res 15(7):2397\u2013405","journal-title":"Clin Cancer Res"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-011-9732-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-011-9732-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-011-9732-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-011-9732-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:31:20Z","timestamp":1678559480000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-011-9732-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,1]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["9732"],"URL":"https:\/\/doi.org\/10.1007\/s10637-011-9732-3","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,1]]},"assertion":[{"value":"27 May 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}